P-4 The relationship between quality of life, adverse events, and treatment efficacy in treatment with first-line chemotherapy plus cetuximab for unresectable metastatic colorectal cancer: Results of phase II QUACK trial.

MLA

Akira, O., et al. “P-4 The Relationship between Quality of Life, Adverse Events, and Treatment Efficacy in Treatment with First-Line Chemotherapy plus Cetuximab for Unresectable Metastatic Colorectal Cancer: Results of Phase II QUACK Trial.” Annals of Oncology, vol. 31, July 2020, p. S90. EBSCOhost, https://doi.org/10.1016/j.annonc.2020.04.086.

APA

Akira, O., Morita, S., Iwamoto, S., Hara, H., Tanioka, H., Satake, H., Kataoka, M., Tsuji, A., Ando, M., Sakamoto, J., & Yamaguchi, K. (2020). P-4 The relationship between quality of life, adverse events, and treatment efficacy in treatment with first-line chemotherapy plus cetuximab for unresectable metastatic colorectal cancer: Results of phase II QUACK trial. Annals of Oncology, 31, S90. https://doi.org/10.1016/j.annonc.2020.04.086

Chicago

Akira, O., S. Morita, S. Iwamoto, H. Hara, H. Tanioka, H. Satake, M. Kataoka, et al. 2020. “P-4 The Relationship between Quality of Life, Adverse Events, and Treatment Efficacy in Treatment with First-Line Chemotherapy plus Cetuximab for Unresectable Metastatic Colorectal Cancer: Results of Phase II QUACK Trial.” Annals of Oncology 31 (July): S90. doi:10.1016/j.annonc.2020.04.086.